Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.39 |
| ▸ | F2 | P00734 | 5/20 | 0.35 |
| ▸ | F10 | P00742 | 3/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7372378 | 1.00 | ITGB3 (0.39) | ITGB3ITGA2BF2F10PRSS1 | |
| SCHEMBL22907553 | 0.84 | MIF (0.48) | MIFHDAC6 | |
| SCHEMBL8128138 | 0.82 | ITGB3 (0.30) | ITGB3ITGA2B | |
| SCHEMBL8128142 | 0.82 | ITGB3 (0.30) | ITGB3ITGA2B | |
| Formic Acid SCHEMBL7373293 | 0.82 | F2 (0.33) | ITGB3ITGA2BF2MIFHDAC6 | |
| SCHEMBL8125406 | 0.82 | ITGB3 (0.30) | ITGB3ITGA2B | |
| SCHEMBL7370488 | 0.81 | KDM1A (0.33) | F2MIFHDAC6 | |
| SCHEMBL7401822 | 0.79 | ITGB3 (0.57) | ITGB3ITGA2BF2F10 | |
| SCHEMBL8114641 | 0.78 | ITGB3 (0.32) | ITGB3ITGA2BF2F10PRSS1 | |
| SCHEMBL7438736 | 0.77 | ITGB3 (0.53) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0832077-B1 | IMPROVED ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARM CO (US) | 2001-11-14 | — | — | EP | disclosed |
| US-5811441-A | INHIBITION OF PLATELET AGGREGATION; TREATMENT OF AUTOIMMUNE DISEASES | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-09-22 | — | — | US | disclosed |